Spondyloarthropathies News

Recently published results showed that although young individuals with inflammatory arthritis place value on treatment that helps them live a normal life, there are profound and lasting emotional, social and vocational consequences of treatment.

The FDA has approved Erelzi for all indications included in the reference product label, including rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and polyarticular juvenile idiopathic arthritis.

Patients with ankylosing spondylitis had lower disease activity and better sleep quality after treatment with anti-tumor necrosis factor therapy compared with NSAIDs, according to results.

A Crohn’s disease patient who complains of joint pain should first be queried as to the location, character (presence or absence of inflammatory features), associated musculoskeletal features of a seronegative spondyloarthropathy and correlation of joint pain to the activity of the Crohn’s Disease.

CLEVELAND — At the Rheumatology Nurses Annual Conference, Christopher T. Ritchlin, MD, MPH, professor and chief at the University of Rochester  Department of Medicine, Immunology, Allergy and Rheumatology division, discussed the role of rheumatology nurses in the treatment of spondyloarthropathies.

CLEVELAND — Rheumatologic health care providers need to look all aspects of psoriasis, including the patient perspective, to determine whether patients warrant systemic or biologic therapies, according to a presenter here at the Rheumatology Nurses Society Annual Conference.

CLEVELAND — Use of appropriate equipment and technique may ensure the comfort of patients who receive joint aspiration and injections in rheumatology practices, said a presenter at the Rheumatology Nurses Society Annual Conference.

Investigators of this study found mucosal-associated invariant T cells may play a role in the pathogenesis of ankylosing spondylitis.

A multi-country prospective observational study showed patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis had comparable clinical features and disease burden and experienced a long delay in referral to rheumatologists.

Samsung Bioepis, a joint venture between Samsung BioLogics and Biogen, announced the European Medicines Agency has accepted for review the marketing authorization application for SB5, an adalimumab biosimilar candidate referencing AbbVie’s Humira.